Beam Therapeutics (NASDAQ: BEAM)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by BMO Capital on Friday, June 17, 2022. The analyst firm set a price target for 41.00 expecting BEAM to rise to within 12 months (a possible 3.04% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $39.79 last updated July 1, 2022, 8:00 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.